I ntegrins are ␣and ␤-subunit heterodimeric receptors that mediate divalent cation-dependent cell-cell and cell-matrix adhesion through tightly regulated interactions with ligands central to inflammation, immunity, hemostasis, and tumor metastasis. 1 Integrins have been viewed to function within a 2-state model. In response to cell activation signals, integrins switch from a low-affinity to a high-affinity ligand-binding state. These inactive and active integrin conformations have been corroborated structurally. 2 In this issue of Circulation Research, Wolf and coworkers 3 have mapped a novel interaction site within the ligand-binding I-domain of the ␣ Msubunit. Taken with the synthesis herein, these data provide tantalizing evidence that the 2-state model of integrin activation and deactivation may be oversimplified.
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Recruitment of circulating leukocytes in inflammation requires multistep adhesive and signaling events mediated, in part, by members of the ␤ 2 -integrin family, LFA-1 (␣ L ␤ 2 , CD11a/CD18), Mac-1 (␣ M ␤ 2 , CD11b/CD18), p150,95 (␣ M ␤ 2 , CD11c/CD18), and ␣ D ␤ 2 (CD11d/CD18). 4 Mac-1 is the most abundant ␤ 2 -integrin on neutrophils and monocytes and is a highly promiscuous receptor, capable of binding a broad repertoire of ligands (Figure, A) and facilitating key leukocyte functions including migration, coagulation, proteolysis, phagocytosis, oxidative burst, and signaling. [5] [6] [7] [8] [9] Elegant structural studies by several groups have begun to elucidate the molecular basis for such broad ligand recognition by Mac-1. A subset of integrin ␣-subunits, including ␣ M of Mac-1, contains an inserted domain (I domain) of Ϸ200 amino acids that is implicated in ligand binding. The ␣ M I-domain contributes broadly to the recognition of ligands by ␣ M ␤ 2 , 10,11 and the binding sites for C3bi, neutrophil inhibitory factor (NIF), fibrinogen, and GPIb␣ have been mapped extensively [12] [13] [14] [15] [16] [17] (Figure, B) . These studies suggest that overlapping but not identical sites are involved in the recognition of C3bi, fibrinogen, NIF, and GPIb␣. 17, 18 Ustinov and Plow have proposed a mosaic model in which many of the same loops and helices of the ␣ M I-domain, on or near its MIDAS face, may engage ligands, but different amino acid residues within these structures may contact the ligands. 15 Direct support for this mosaic model is seen within the K 245 -R 261 segment of the ␣ M I-domain, which has been implicated in both NIF and fibrinogen recognition. 16 Key contact amino acids in this loop for fibrinogen binding are F 246 , D 254 , and P 257 , whereas Y 252 and E 258 are involved in NIF binding. This same ␣ M I-domain segment is also involved in C3bi recognition by ␣ M ␤ 2 . 18 Wolf and colleagues 3 report that the binding of CD40L to Mac-1 involves the 162 EQLKKSKTL 170 sequence in the ␣ M I-domain and promotes leukocyte recruitment and atherosclerosis but apparently does not affect immunity (mediated by CD40L-CD40) and thrombosis (mediated by CD40L-GPIIb/IIIa) in mice. The authors used a peptide mapping strategy described by Ehlers and coworkers 17 for identifying the GPIb␣ binding site in Mac-1 (␣ M I-domain P 201 -K 217 sequence, termed M2), in which a series of linear peptides corresponding to the hydrated surface of Mac-1's I-domain were assayed for their ability to inhibit Mac-1-CD40L. The importance of the 162 EQLKKSKTL 170 sequence in binding to CD40L was confirmed by the lack of binding of a chimeric ␣ M integrin in which the E 162 -L 170 sequence was swapped with the corresponding ␣ L ␤ 2 sequence. Interestingly, the region corresponding to M7 (E 162 -L 170 ), located on an exposed loop between the ␣1 helix and ␤-sheet B in the tertiary structure of the ␣ M I-domain, has not been implicated in binding of GPIb␣, NIF, C3bi, ICAM-1, or fibrinogen to Mac-1 (Figure, B) . The M7 peptide had no effect of Mac-1 binding to GPIb␣, ICAM-1, and fibrinogen. To evaluate the physiological role of Mac-1-CD40L binding, a cyclic version of M7 (cM7) was synthesized and found to inhibit chemical peritonitis and atherosclerotic lesion formation. The specificity of cM7 for Mac-1-CD40L was established by showing that it did not interfere with CD40L-CD40 (cytokine production) or CD40L-GPIIb/IIIa (bleeding time and thrombosis) signaling and function.
The present observations suggest a possible target for therapeutic intervention in cardiovascular disease. In particular, the specificity of M7 inhibitory action toward CD40L, and similarly of M2 inhibitory action toward GP Ib␣ (ie, noninhibitory toward multiple other Mac-1 ligands), suggests that it might be possible to prevent leukocyte attachment to endothelium and platelets by targeting CD40L and GPIb␣, respectively, without inhibiting other ␣ M ␤ 2 functions. For example, our prior work has identified ␣ M ␤ 2 as a molecular determinant of neointimal hyperplasia after arterial wire injury that produces endothelial denudation and platelet deposition. We found that selective absence of ␣ M ␤ 2 impaired transplatelet leukocyte migration into the vessel wall, diminishing medial leukocyte accumulation, cellular proliferation, and neointimal formation. 19 Follow-on studies indicate that the interaction of ␣ M ␤ 2 with GPIb␣ interaction probably is solely responsible for Mac-1's action in this disease model because anti-M2 antibody targeting produced the identical effect. Targeting ␣ M ␤ 2 -GPIb␣ binding with anti-M2 has also elucidated an important role for leukocyte-platelet interactions in models of vasculitis 20 and glomerulonephritis. 21 The work of Wolf and coworkers confirms that highly selective inhibition of one particular Mac-1 function is a reasonable approach to attenuate atherosclerotic lesion formation without the untoward prothrombotic effects observed clinically with antibody targeting of CD40L. Furthermore, the binding of fibrinogen to Mac-1 plays an important role in the inflammatory response to biomaterials. 22 Highly selective inhibitors of Mac-1-fibrinogen have been synthesized 23 and thus may be useful in modifying the inflammatory response to implantable devices.
Perhaps the most important lesson from this study is that integrins appear to share the features of "biased agonism," or differential signaling that characterize the 7-transmembrane superfamily of receptors (G-protein coupled receptors). 24 A large body of data suggests that the traditional agonist model for G-protein coupled receptors, in which a common active state induces uniform downstream signaling, is oversimplified with some agonists producing activation of some but not all available pathways. These agonists are "biased" in as much as they select for one signaling pathway over another. Notably, engagement of Mac-1 by fibrinogen induces activation of NF-kB 9, 25 and downregulation of the forkhead transcription factor Foxp1 26, 27 (a signaling pathway that regulates monocyte differentiation in vitro and in vivo), whereas the engagement of Mac-1 by CD40L did not induce NF-kB activation or inflammatory gene expression. The reason for this differential signaling is unknown but raises tantalizing questions: Is differential signaling by distinct ligands secondary to unique allosteric interactions? If so, do integrins adopt multiple activation states, reflecting a shift in equilibrium among multiple conformational states in response to one or more inputs, similar to fluctuations in energy landscapes of enzymes-and to be contrasted with a classic 2-state model (low-and high-affinity states for ligand)? Does the binding of specific ligands promote unique proteinprotein interactions with the cytoplasmic tails of integrins, reflecting alternative conformations? Could small molecules or antibodies be identified and used to induce or inhibit these particular activation states and thereby manipulate downstream signals? Thus, in addition to the multifunctional properties of Mac-1, reflecting a highly promiscuous ligand-binding repertoire, biased signaling may endow the integrin receptor with highly specialized responses. We hope that further understanding of the structural basis for this differential ligand-induced signaling can be exploited to exact specific biological responses for therapeutic gain. 
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